Mazindol controlled release - NLS Pharma

Drug Profile

Mazindol controlled release - NLS Pharma

Alternative Names: NLS 0; NLS 1

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NLS Pharma
  • Class Anorectics; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Narcolepsy
  • Phase II Attention-deficit hyperactivity disorder

Most Recent Events

  • 05 Jun 2018 Phase-III clinical trials in Narcolepsy (PO) (NLS Pharma pipeline, June 2018)
  • 31 Oct 2017 Updated adverse events and efficacy data from a phase II trial in Attention-deficit hyperactivity disorder released by NLS Pharma
  • 22 Jun 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top